Elder Pharmaceuticals, an integrated pharmaceuticals company, has posted 22 per cent rise in its consolidated net profit at Rs 23.60 crore for the quarter ended September 2012 compared to Rs 19.35 crore for the corresponding period previous year. Total consolidated income also jumped similarly to Rs 404.06 crore during the Q2, 2013 compared to Rs 331.08 crore in the same period last year.
During the quarter under review, the company launched eight new products namely moclawin tablet (antibiotic), enzar HS (digestive enzyme), elpod-o (antibiotic), D-360 capsule and D-all (vitamin D), daposure (erectile dysfunction/premature ejaculation), new zephrol (cold) and pentastatic capsule (pre-probiotics).
“Various international alliances of the company, new manufacturing facilities, launch of newer products, penetration into rural and semi-urban markets and strong growth in the traditional products have contributed to the company’s better working,” said Alok Saxena, Managing Director, Elder Pharmaceuticals Ltd.
Elder Pharmaceuticals has presence in niche therapeutic segments like women’s healthcare, wound care, nutraceuticals /vitamin supplements, cardiology, diabetes, dermatology, antibiotics and neurology.
It is the market leader in calcium supplements, wound healing and injectable B12 vitamin. The company has a judicious mix of drug formulations, and active pharma ingredients (APIs).
It has 6 manufacturing plants in India located in Maharashtra, Uttarakhand and Himachal Pradesh.
The company has a state-of-the-art Research & Development Centre at Navi Mumbai which is recognized by the Department of Scientific & Industrial Research, Ministry of Science & Technology.
